Medscape

ACUITY and ACUITY Timing: Heparin, GP IIb/IIIa inhibitors (Upstream vs Deferred Use), and Bivalirudin -- Managing Moderate- to High-Risk ACS Patients

"The amount of data obtained are overwhelming and will need careful interpretation due to the study's significant implications, which may change the way adjuvant anticoagulation is given to ACS ...
Medscape

'Judicious' GP IIb/IIIa Inhibitor Use at PCI Recommended

KANSAS CITY, MO — In a large observational study of patients who had nonelective PCI for ACS, those who received a glycoprotein IIb/IIIa inhibitor (GPI) had a lower risk of all-cause in-hospital ...
TCTMD

TCT 235: Efficacy and Safety of Bivalirudin and Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients Who Underwent Percutaneous Coronary Intervention: A ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Healio

Trial Scorecard: CELEBRATE

Please provide your email address to receive an email when new articles are posted on . The CELEBRATE trial evaluated efficacy and safety of a novel subcutaneous glycoprotein IIb/IIIa inhibitor ...